CClinicalTrials.gg
CompletedNCT04999358Updated Apr 9, 2025

Protein Intake in Patients With Coronary Heart Disease

An interventional study of Protein education and Standard education in Coronary Heart Disease, Low Protein Intake and Sarcopenia, sponsored by Northumbria University. Completed at 1 site in United Kingdom. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2025-04-09.

Sponsored by Northumbria University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
50 Years and older
Sex
All
01

Study summary

Sarcopenia is a skeletal muscle disease, characterised by low muscle strength and muscle mass, and associated with higher medical care costs, shorter life expectancy and physical dependence. Sarcopenia affects around 1 in 10 older adults in the general population. However, in patients with coronary heart disease (CHD), this number is almost 3 in 10. Patients who have CHD are offered cardiac rehabilitation (CR); a multicomponent programme designed to improve long-term health outcomes. Nutritional education is an important part of CR and typically focuses around modifying fat and carbohydrate intake to lower cholesterol levels and achieve a healthy weight. Currently there is little focus on increasing protein intake, which might reduce the risk of sarcopenia. Eligible patients with CHD and low protein intake will receive the standard nutritional education delivered during CR. Next, participants will be randomised to one of two groups: protein education (intervention), or standard information (control). Whilst COVID-19 restrictions are in place, education will be delivered remotely via pre-recorded video. Outcome measures, including protein intake, sit to stand performance, sarcopenia risk score (modified SARC-F), Physical Activity Vital Signs (PAVS) and waist circumference, will be assessed at baseline, at the end of the standard CR programme and after a follow-up period of the same duration as the CR programme.

02

Conditions studied

  • Coronary Heart Disease
  • Low Protein Intake
  • Sarcopenia

Keywords

  • Protein
  • Coronary heart disease
  • Rehabilitation
  • Telehealth
03

In context

Sarcopenia

1,208 studies on the registry are indexed under Sarcopenia; 402 are open to participants now.

This study's enrollment of 35 is below the median of 60 across 775 interventional studies indexed under Sarcopenia.

Browse Sarcopenia studies →

Lead sponsor

Northumbria University is the lead sponsor of 156 studies on the registry; 22 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Aged 50 years or older.
  • Recent diagnosis of coronary heart disease or a cardiac event related to coronary heart disease.
  • Have been offered standard cardiac rehabilitation in a Newcastle upon Tyne Hospitals NHS Foundation Trust.
  • Usually receive dietary education as part of their cardiac rehabilitation program.
  • Able to understand and undertake the tasks described as part of this study.
  • Able to provide written informed consent.

Exclusion criteria

Exclusion Criteria:

  • Patients advised against participation in light exercise by a medical professional.
  • Patients younger than 50 years.
  • Patients unable to alter their diet due to medical reasons; including patients that have been prescribed artificial feeding, texture modified diets, and specialist renal diets.
  • Patients with known stage 4 or 5 chronic kidney disease.
  • Patients without access to teleconferencing technology or without another adult present (≥18 years; and with capacity to supervise the activity) will be excluded from participating in the remote sit-to-stand test for their safety.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Protein group

    Participants in the protein group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the protein group will be provided with an additional targeted protein education session, which will aim to increase the amount of foods eaten with protein in them (≥1.2 g/kg protein/day) and improve the quality of protein sources that are eaten. The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD

    Behavioral: Protein education

  • Placebo comparator
    Control group

    Participants in the control group will receive their usual education session(s) as part of standard practice cardiac rehabilitation. The session(s) will be the same for both study arms and will align with the dietary education sessions that these patients would usually be given during their normal cardiac rehabilitation programme. Participants in the control group will receive an additional dietary education session that is similar to the standard practice sessions, containing only information that is usually provided in the cardiac rehabilitation programme.The content and materials for these sessions can be provided in-person or are available as pre-recorded videos, accessed by participants via the internet or DVD.

    Behavioral: Standard education

Interventions

  • BehavioralProtein education

    The protein education session is pre-recorded and will describe in lay terms: the health issues associated with low protein intake, the amount of protein to eat in a day, and provide useful information to increase protein intake. This information will focus on the quality and amount of protein eaten, primarily using a whole-food approach. For example, the education sessions will give ideas for everyday foods that can be added to regular meals, favouring plant proteins, fish, lean meat, poultry, low fat dairy and eggs. The education session has been provided in conjunction with an NHS dietitian.

  • BehavioralStandard education

    Dietary advice provided as part of standard cardiac rehabilitation will be pre-recorded and provided to the control group. This education session will be in addition to usual care.

06

What researchers measure

Primary outcomes

  1. Change in protein intake (g/kg/day).

    Between-group intervention effect for dietary protein intake in the intervention and control groups. Protein intake is assessed with a three-day food diary.

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

Secondary outcomes

  1. Prevalence of low protein intake in patients with coronary heart disease.

    Average protein intake and percentage of participants with protein intake \<1.2 g/kg/day and \<0.8 g/kg/day.

    Time frame: Baseline, up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  2. Change in sit to stand performance (leg strength).

    Between-group intervention effect for sit to stand performance in the intervention and control groups. The time taken to complete five consecutive sit to stands will be recorded.

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  3. Change in sarcopenia risk score and self-reported physical activity.

    Between-group intervention effect for questionnaire scores in the intervention and control groups. Sarcopenia risk and physical activity are assessed using the modified SARC-F questionnaire (SARC-F+EBM; includes age and body mass index) and Physical Activity Vital Signs questionnaire (PAVS), respectively.

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  4. Difference in protein intake between patients with and without probable sarcopenia.

    Probable sarcopenia is assessed using sit to stand time. The cut-off point for probable sarcopenia will be \>15seconds to complete five sit to stands, as proposed by the European Working Group on Sarcopenia in Older People-2.

    Time frame: Baseline, up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  5. Change in waist circumference.

    Between-group intervention effect for waist circumference will be assessed as a simple indicator of body composition.

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  6. Reliability of self-assessed waist circumference.

    Whilst COVID-19 restrictions are in place, participants will be required to complete their own waist circumference measurement. Measures will be taken 24 hours apart to determine their reliability.

    Time frame: 24 hours.

  7. Adherence

    Adherence will be assessed as the amount of education sessions completed by participants, as a percentage of those prescribed.

    Time frame: Up to 12 weeks.

  8. Attrition.

    Attrition will be assessed as the percentage of participants that drop out of the intervention before the study period is complete.

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  9. Occurrence of adverse events

    Adverse events (such as injury or illness) that are directly related to the intervention will be reported..

    Time frame: Up to 12 weeks and up to 24 weeks; time points determined by CR standard duration.

  10. Understanding and evaluation of the intervention.

    A short questionnaire will determine patients' understanding of the educational material and their evaluation of the intervention

    Time frame: Baseline and up to 12 weeks.

07

Study locations

1 site
  • Newcastle upon Tyne Hospitals NHS Trust
    Newcastle Upon Tyne, NE7 7DN, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04999358
Lead sponsor
Northumbria University
Collaborators
Newcastle-upon-Tyne Hospitals NHS Trust
Responsible party
Emily James (Principal Investigator, Northumbria University) — Principal investigator
First posted
Aug 10, 2021
Start date
Nov 29, 2021
Primary completion
Sep 12, 2023
Completion
Sep 12, 2023
Last update
Apr 9, 2025

Study contacts

Alasdair O'Doherty, PhD
study chair · University of Northumbria at Newcastle

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion